168 related articles for article (PubMed ID: 26979156)
1. Rational modification of the lead molecule: Enhancement in the anticancer and dihydrofolate reductase inhibitory activity.
Kaur J; Kaur S; Singh P
Bioorg Med Chem Lett; 2016 Apr; 26(8):1936-40. PubMed ID: 26979156
[TBL] [Abstract][Full Text] [Related]
2. 2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes.
Piras S; Carta A; Briguglio I; Corona P; Paglietti G; Luciani R; Costi MP; Ferrari S
Eur J Med Chem; 2014 Mar; 75():169-83. PubMed ID: 24531230
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors.
Zhou X; Lin K; Ma X; Chui WK; Zhou W
Eur J Med Chem; 2017 Jan; 125():1279-1288. PubMed ID: 27886545
[TBL] [Abstract][Full Text] [Related]
4. Study of reactivity of cyanoacetohydrazonoethyl-N-ethyl-N-methyl benzenesulfonamide: preparation of novel anticancer and antimicrobial active heterocyclic benzenesulfonamide derivatives and their molecular docking against dihydrofolate reductase.
Debbabi KF; Al-Harbi SA; Al-Saidi HM; Aljuhani EH; Abd El-Gilil SM; Bashandy MS
J Enzyme Inhib Med Chem; 2016; 31(sup4):7-19. PubMed ID: 27557134
[TBL] [Abstract][Full Text] [Related]
5. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Ng HL; Chen S; Chew EH; Chui WK
Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
[TBL] [Abstract][Full Text] [Related]
6. Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents.
Singh P; Kaur M; Sachdeva S
J Med Chem; 2012 Jul; 55(14):6381-90. PubMed ID: 22734697
[TBL] [Abstract][Full Text] [Related]
7. Thiazolo[4,5-d]pyridazine analogues as a new class of dihydrofolate reductase (DHFR) inhibitors: Synthesis, biological evaluation and molecular modeling study.
Ewida MA; Abou El Ella DA; Lasheen DS; Ewida HA; El-Gazzar YI; El-Subbagh HI
Bioorg Chem; 2017 Oct; 74():228-237. PubMed ID: 28865294
[TBL] [Abstract][Full Text] [Related]
8. Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
Gao T; Zhang C; Shi X; Guo R; Zhang K; Gu J; Li L; Li S; Zheng Q; Cui M; Cui M; Gao X; Liu Y; Wang L
Eur J Med Chem; 2019 Sep; 178():329-340. PubMed ID: 31200235
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel 6-substituted pyrrolo [3,2-d] pyrimidine analogues as antifolate antitumor agents.
Tian C; Wang M; Han Z; Fang F; Zhang Z; Wang X; Liu J
Eur J Med Chem; 2017 Sep; 138():630-643. PubMed ID: 28711701
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of antitumor acylated monoaminopyrroloquinazolines.
Chao B; Li BX; Xiao X
Bioorg Med Chem Lett; 2017 Jul; 27(14):3107-3110. PubMed ID: 28552339
[TBL] [Abstract][Full Text] [Related]
11. Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims').
Richardson ML; Croughton KA; Matthews CS; Stevens MF
J Med Chem; 2004 Jul; 47(16):4105-8. PubMed ID: 15267250
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, dihydrofolate reductase inhibition, anti-proliferative testing, and saturation transfer difference ¹H-NMR study of some new 2-substituted-4,6-diaminopyrimidine derivatives.
Mohebbi S; Falcón-Pérez JM; González E; Millet O; Mato JM; Kobarfard F
Chem Pharm Bull (Tokyo); 2012; 60(1):70-8. PubMed ID: 22223377
[TBL] [Abstract][Full Text] [Related]
13. Antifolate and antiproliferative activity of 6,8,10-triazaspiro[4.5]deca-6,8-dienes and 1,3,5-triazaspiro[5.5]undeca-1,3-dienes.
Ma X; Chui WK
Bioorg Med Chem; 2010 Jan; 18(2):737-43. PubMed ID: 20036565
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel antifolate analogs as potential anticancer treatment.
Stoicescu DF; Rotaru M
Anticancer Agents Med Chem; 2013 Feb; 13(2):364-72. PubMed ID: 23157590
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
Gangjee A; Lin X; Kisliuk RL; McGuire JJ
J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
[TBL] [Abstract][Full Text] [Related]
16. Human dihydrofolate reductase inhibition effect of 1-Phenylpyrazolo[3,4-d]pyrimidines: Synthesis, antitumor evaluation and molecular modeling study.
Salem IM; Mostafa SM; Salama I; El-Sabbagh OI; A H Hegazy W; Ibrahim TS
Bioorg Chem; 2022 Dec; 129():106207. PubMed ID: 36270170
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido[3,2-d]pyrimidines with a three- to five-carbon bridge.
Li H; Fang F; Liu Y; Xue L; Wang M; Guo Y; Wang X; Tian C; Liu J; Zhang Z
Bioorg Med Chem; 2018 May; 26(9):2674-2685. PubMed ID: 29691154
[TBL] [Abstract][Full Text] [Related]
18. Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling investigations.
Zink M; Lanig H; Troschütz R
Eur J Med Chem; 2004 Dec; 39(12):1079-88. PubMed ID: 15571870
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological evaluation and molecular modeling study of new (1,2,4-triazole or 1,3,4-thiadiazole)-methylthio-derivatives of quinazolin-4(3H)-one as DHFR inhibitors.
El-Gazzar YI; Georgey HH; El-Messery SM; Ewida HA; Hassan GS; Raafat MM; Ewida MA; El-Subbagh HI
Bioorg Chem; 2017 Jun; 72():282-292. PubMed ID: 28499189
[TBL] [Abstract][Full Text] [Related]
20. Triazine-benzimidazole hybrids: anticancer activity, DNA interaction and dihydrofolate reductase inhibitors.
Singla P; Luxami V; Paul K
Bioorg Med Chem; 2015 Apr; 23(8):1691-700. PubMed ID: 25792141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
